Comparison of diagnostic value of I-123 MIBG and high-dose I-131 MIBG scintigraphy including incremental value of SPECT/CT over planar image in patients with malignant pheochromocytoma/paraganglioma and neuroblastoma

Clinical Nuclear Medicine

Volumn 36, Issue 1, 2011, Pages 1-7

  Fukuoka, Makoto ^a   Taki, Junichi ^a   Mochizuki, Takafumi ^a   Kinuya, Seigo ^b  

^a KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

I 123 MIB; I 131 MIBG; malignant neuroendocrine tumor; SPECT CT

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DRUG MEGADOSE; FEMALE; HUMAN; MALE; NEUROBLASTOMA; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PLANAR IMAGE; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

3-IODOBENZYLGUANIDINE; ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; AGED; CHILD; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEUROBLASTOMA; PARAGANGLIOMA; PHEOCHROMOCYTOMA; RADIONUCLIDE IMAGING; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 78651098648     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3181feeb5e     Document Type: Article

References (33)

1. Jaques S, Tobes MC, Sisson JC. Sodium dependency of uptake of norepinephrine and m-iodobenzylguanidine into cultured human pheochromocytoma cells: evidence for uptake-one. Cancer Res. 1987;47:3920-3928.
2. Gasnier B, Roisin MP, Scherman D, et al. Uptake of metaiodobenzylguanidine by bovine chromaffin granule membranes. Mol Pharmacol. 1986;29: 275-280.
3. Edström Elder E, Hjelm Skog AL, Höög A, et al. The management of benign and malignant pheochromocytoma and abdominal paraganglioma. Eur J Surg Oncol. 2003;29:278-283.
4. Whalen RK, Althausen AF, Daniels GH. Extra-adrenal pheochromocytoma. J Urol. 1992;147:1-10.
5. Lonergan GF, Schwab CM, Suarez ES, et al. From the archives of the AFIP neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: radiologicpathologic correlation. Radiographics. 2002;29:911-934.
6. Papaioannou G, McHugh K. Neuroblastoma in childhood: review and radiological findings. Cancer Imaging. 2005;5:116-127.
7. Sisson JC, Frager MS, Valk TW, et al. Scintigraphic localization of pheochromocytoma. N Engl J Med. 1981;305:12-17.
8. Shapiro B, Copp JE, Sisson JC, et al. Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J Nucl Med. 1985;26:576-585. (Pubitemid 16033416)
9. Boubaker A, Bischof Delaloye A. MIBG scintigraphy for the diagnosis and follow-up of children with neuroblastoma. Q J Nucl Med Mol Imaging. 2008;52:388-402.
10. van der Harst E, de Herder WW, Bruining HA, et al.I-123- metaiodobenzylguanidine and-In-111-octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab. 2001;86:685-693.
11. van der Horst-Schrivers AN, Jager PL, Boezen HM, et al. Iodine-123 metaiodobenzylguanidine scintigraphy in localising phaeochromocytomas- experience and meta-analysis. Anticancer Res. 2006;26:1599-1604.
12. Bhatia KS, Ismail MM, Sahdev A, et al. 123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clin Endocrinol (Oxf). 2008;69: 181-188.
13. Wiseman GA, Pacak K, ODorisio MS, et al. Usefulness of I-123 MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial. J Nucl Med. 2009;50:1448-1454.
14. Shulkin BL, Shapiro B, Francis IR, et al. Primary extra-adrenal pheochromocytoma: positive I-123 MIBG imaging with negative I-131 MIBG imaging. Clin Nucl Med. 1986;11:851-854.
15. Lynn MD, Shapiro B, Sisson JC, et al. Pheochromocytoma and the normal adrenal medulla: improved visualization with I-123 MIBG scintigraphy. Radiology. 1985;156:789-792.
16. Campbell L, Mouratidis B, Sullivan P. Improved detection of disseminated pheochromocytoma using post therapy I-131 MIBG scanning. Clin Nucl Med. 1996;21:960-963.
17. Iwano S, Kato K, Nihashi T, et al. Comparisons of I-123 diagnostic and I-131 post-treatment scans for detecting residual thyroid tissue and metastases of differentiated thyroid cancer. Ann Nucl Med. 2009;23:777-782.
18. Weber DA, Ivanovic M. Correlative image registration. Semin Nucl Med. 1994;24:311-323.
19. Pérault C, Schvartz C, Wampach H, et al. Thoracic and abdominal SPECT-CT image fusion without external markers in endocrine carcinomas. J Nucl Med. 1997;38:1234-1242.
20. Hutton BF, Braun M, Thurfjell L, et al. Image registration: an essential tool for nuclear medicine. Eur J Nucl Med. 2002;29:559-577.
21. Even-Sapir E, Keidar Z, Sachs J, et al. The new technology of combined transmission and emission tomography in evaluation of endocrine neoplasms. J Nucl Med. 2001;42:998-1004.
22. Pfannenberg AC, Eschmann SM, Horger M, et al. Benefit of anatomicalfunctional image fusion in the diagnostic work-up of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging. 2003;30:835-843.
23. Schillaci O. Functional-anatomical image fusion in neuroendocrine tumors. Cancer Biother Radiopharm. 2004;19:129-134.
24. Moreila PP, Duarte LH, Vieira F, et al. Value of SPECT/CT image fusion in the assessment of neuroendocrine tumours with In-111 pentetreotide scintigraphy. Rev Esp Med Nucl. 2005;24:14-18.
25. Anthauer H, Denecke T, Rohlfing T, et al. Value of image fusion using single photon emission computed tomography with integrated low dose computed tomography in comparison with a retrospective voxel-based method in neuroendocrine tumours. Eur Radiol. 2005;15:1456-1462.
26. Rozovsky K, Koplewitz B, Krausz Y, et al. Added value of SPECT/CT for correlation of MIBG scintigraphy and diagnostic CT in neuroblastoma and pheochromocytoma. AJR. 2008;190:1085-1090.
27. Sisson JC, Shapiro B, Beierwaltes WH, et al. Radiopharmaceutical treatment of malignant pheochromocytoma. J Nucl Med. 1984;24:197-206.
28. Gedik GK, Hoefnagel CA, Bais E, et al. I-131 MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2008;35:725-733.
29. Gonias S, Goldsby R, Matthay KK, et al. Phase II study of high-dose-I-131-metaiodebenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol. 2009;27:4162-4168.
30. DuBois SG, Matthay KK. Radiolabeled metaiodebenzylguanidine for the treatment of neuroblastoma. Nucl Med Biol. 2008;35:35-48.
31. Scholz T, Eisenhofer G, Pacak K, et al. Clinical review: current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab. 2007;92:1217-1225.
32. Roach PJ, Schembri GP, Ho Shon IA, et al. SPECT/CT imaging using a spiral CT scanner for anatomical localization: impact on diagnostic accuracy and reporter confidence in clinical practice. Nucl Med Commun. 2006;27:977-987.
33. Chen L, Luo Q, Shen Y, et al. Incremental value of I-131 SPECT/CT in the management of patients with differentiated thyroid cancer. J Nucl Med. 2008;49:1952-1957.